These 22 pharmaceutical companies are bright!

A few days ago, the official website of the Ministry of Industry and Information Technology announced the results of the review and evaluation of national technological innovation demonstration enterprises in 2021
.

List of national technological innovation demonstration pharmaceutical companies that have passed the review and evaluation in 2021

CSPC: Two-wheel drive of innovation and internationalization

CSPC's revenue and R&D investment (unit: 100 million yuan)

CSPC is a national-level innovative enterprise integrating R&D, production and sales of innovative drugs
.

CSPC has always adhered to innovative R&D strategies and continued to increase R&D investment.
The compound growth rate of R&D expenses in the past three years has reached 46.
7%
.

Recently, CSPC has received frequent reports
.

Renfu Medicine: To be a leader in the pharmaceutical market segment

Renfu Pharmaceutical's revenue and R&D investment (unit: 100 million yuan)

Renfu Medicine adheres to the development strategy of "being a leader in the pharmaceutical market segment".
After more than 20 years of development, the company has formed a leading or leading position in the neurologic drugs, steroid hormone drugs, and Uyghur ethnic medicine.
It is gradually expanding its generic drug business in the United States and maintaining a steady momentum of development
.

Renfu Medicine continues to increase investment in research and development.
While advancing the development of generic drugs, it accelerates the progress of new drug research and development, forms a competitive product echelon, and continues to upgrade to ensure the company's long-term sustainable development
.

On September 22, Renfu Medicine issued an announcement on the company’s actual controller and chairman of the company’s shareholding plan.
The actual controller Ai Luming and chairman Li Jie planned to use their own funds within 6 months from the date of the announcement.
Increase the shareholding of the company, and the total amount of the increase shall not be less than 20 million yuan and not more than 40 million yuan
.

Huahai Pharmaceutical: Continue to accelerate industrial transformation and upgrading, and promote preparation globalization strategy

Huahai Pharmaceutical's revenue and R&D investment (unit: 100 million yuan)

Huahai Pharmaceutical is a large-scale high-tech pharmaceutical enterprise integrating pharmaceutical R&D, manufacturing, and sales.
Its main business is pharmaceutical preparations and raw materials, forming cardiovascular, mental disorders, nervous system, and anti-infective products.
Series
.

Huahai Pharmaceutical continues to accelerate the pace of industrial transformation and upgrading, promote the globalization strategy of preparations, improve and optimize the two major industrial chains of preparations and APIs, deepen the two major international and domestic sales systems, continuously improve R&D and innovation capabilities, and accelerate the fields of biological drugs and innovative drugs Development
.
In recent years, the company's R&D investment accounted for more than 10% of its revenue.
In the first half of this year, R&D expenses were 359 million yuan, a year-on-year increase of more than 50%
.
In terms of R&D technology, Huahai Pharmaceutical has established a three-dimensional interactive R&D system in the United States, Shanghai, and Linhai, forming a R&D and technology network that combines imitation and innovation, domestic and foreign integration, and synergy between APIs and preparations; the R&D system covers everything from intermediates, APIs to The complete industrial chain of preparations has the R&D capabilities of high-end generic drugs such as solid slow and controlled release, complex injections, insoluble drug solubilization, first imitation and challenge patented products, as well as biological drugs and innovative drugs; the company has always been based on innovation and development, and strives to build High-tech barrier generic drugs, improved new drugs and new drug molecular design and screening platform
.
It is worth mentioning that after years of development, Huahai Pharmaceutical’s preparation internationalization business has formed an international drug R&D system and talent team from product selection, API and preparation R&D, clinical trials to registration and application.
As of the first half of this year , The company has 1307 R&D personnel
.
Since its development, the company has undertaken 31 national-level science and technology projects, 78 provincial-level science and technology projects, and has won 3 second-class National Science and Technology Progress Awards and 2 China Patent Excellence Awards
.
At present, the company has more than 300 patents, including 67 overseas patents
.

At the beginning of September, Huahai Pharmaceutical issued an announcement stating that the company had been approved for the production of memantine hydrochloride tablets in the 4 types of imitations and was deemed to have been reviewed
.
According to data from Meinenet, the sales of terminal Memantine in China's public medical institutions will exceed 600 million yuan in 2020
.
Huahai Pharmaceutical said that the approval of the product has further enriched the company's product line, will help enhance market competitiveness, and will have a positive impact on the company's operating performance
.

Source: Ministry of Industry and Information Technology official website, public company announcements